Related Experiment Video
Updated: Jul 20, 2026

Purification of the Membrane Compartment for Endoplasmic Reticulum-associated Degradation of Exogenous Antigens in Cross-presentation
Published on: August 21, 2017
Antigen processing/presenting and oncogenesis
1Department of Microbiology & Immunology, Faculty of Medicine, American University of Beirut, Lebanon.
Abstract:
It has been established in recent years that a number of tumor cell types express tumor antigens, yet the host's immune system fails to recognize them. The antigen processing/presenting machinery, which plays a crucial role in generating an immune response, and possible causes for its inability of processing/presenting tumor antigens are reviewed. These causes are related to the expression of major histocompatibility complex molecules, costimulatory molecules, and tumor antigens by tumor cells, and the types of cytokines produced. Therapeutic measures include transfecting tumor cells with genes that encode major histocompatibility complex and costimulatory molecules, cytokines, and tumor antigens. In addition, tumor peptide vaccines are evaluated. However, developing an immune response to tumor antigens carries with it the risk of autoimmune disease.
Insights
The host immune system often fails to recognize tumor antigens due to issues with antigen processing and presentation. Therapeutic strategies like gene therapy and peptide vaccines aim to overcome this, but carry risks of autoimmune disease.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor cells express antigens, but the host immune system fails to recognize them.
- The antigen processing and presentation machinery is critical for initiating an immune response against cancer.
Purpose of the Study:
- To review the causes of immune system failure in processing/presenting tumor antigens.
- To discuss therapeutic strategies for enhancing anti-tumor immunity.
- To highlight the risks associated with inducing immune responses to tumor antigens.
Main Methods:
- Review of existing literature on tumor immunology and antigen presentation.
- Analysis of factors affecting major histocompatibility complex (MHC) and costimulatory molecule expression.
- Evaluation of cytokine profiles in the tumor microenvironment.
Main Results:
- Deficiencies in MHC and costimulatory molecule expression by tumor cells impair immune recognition.
- Tumor cell-intrinsic factors and cytokine milieu contribute to immune evasion.
- Gene therapy (MHC, costimulatory molecules, cytokines, tumor antigens) and tumor peptide vaccines show therapeutic potential.
Conclusions:
- Understanding antigen processing defects is key to developing effective cancer immunotherapies.
- Therapeutic interventions can enhance anti-tumor immune responses but require careful consideration of potential autoimmune side effects.
Related Concept Videos
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

